NCT06140576View on ClinicalTrials.gov

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Breast Neoplasms

Interventions

DRUG

Sindilimab

Sindilimab, 200mg, Intravenous，every three weeks

DRUG

Nab-paclitaxel

Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks

DRUG

Lenvatinib

Lenvatinib 8mg, 12mg, 16mg everyday

Trial Locations (1)

Unknown

ZhejiangCH, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER

NCT06140576 - The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | Biotech Hunter | Biotech Hunter